{"type":"trials","record":{"id":42188,"source_id":"clinicaltrials-gov","external_id":"NCT03710564","title":"Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections","brief_summary":"This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.","overall_status":"Terminated","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":535,"countries":["United States","Puerto Rico"],"start_date":"2018-10-30","completion_date":"2021-07-01","last_update_date":"2023-01-30","source_url":"https://clinicaltrials.gov/study/NCT03710564","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"MERLIN","age_range":"50 Years","comparator":"Aflibercept","organization":"Novartis","interventions":["Brolucizumab","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52 — Baseline, week 52","Stable Visual Acuity (VA) or Improvement in VA at Week 52 and Week 104 — Baseline, weeks 52 and 104","Loss in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Loss in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Loss in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Gain in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Gain in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Gain in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Change in Central Subfield Thickness (CST) From Baseline — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48…","Number of Participants With Intraretinal Fluid (IRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60,…","Number of Participants With Subretinal Fluid (SRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64…","Number of Participants With Sub-Retinal Pigment Epithelium (Sub-RPE) Fluid — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Number of Participants With Fluid-free Status (no IRF, SRF or Sub-RPE Fluid) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36,…","Time to First Dry Retina (no IRF or SRF) — Baseline, Up to Week 104 (assessments every 4 weeks)","Time to Sustained Dry Retina (no IRF or SRF at ≥ 2 Consecutive Visits) — Baseline, Up to Week 104 (assessments every 4…","Number of Participants With Anti-drug Antibody (ADA) Negative Status — Baseline, weeks 4, 12, 24, 36, 52, 76 and 104","Free Brolucizumab Serum Concentration — pre-dose a baseline, weeks 4, 12, 24, 36, 52, 76 and 104"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","Brolucizumab","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03710564","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-10-30 to 2021-07-01","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.933Z","intervention":["Brolucizumab","Aflibercept"],"participants":535,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52 — Baseline, week 52","Stable Visual Acuity (VA) or Improvement in VA at Week 52 and Week 104 — Baseline, weeks 52 and 104","Loss in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Loss in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Loss in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Gain in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Gain in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Gain in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…","Change in Central Subfield Thickness (CST) From Baseline — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48…","Number of Participants With Intraretinal Fluid (IRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60,…","Number of Participants With Subretinal Fluid (SRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64…","Number of Participants With Sub-Retinal Pigment Epithelium (Sub-RPE) Fluid — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…","Number of Participants With Fluid-free Status (no IRF, SRF or Sub-RPE Fluid) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36,…","Time to First Dry Retina (no IRF or SRF) — Baseline, Up to Week 104 (assessments every 4 weeks)","Time to Sustained Dry Retina (no IRF or SRF at ≥ 2 Consecutive Visits) — Baseline, Up to Week 104 (assessments every 4…","Number of Participants With Anti-drug Antibody (ADA) Negative Status — Baseline, weeks 4, 12, 24, 36, 52, 76 and 104","Free Brolucizumab Serum Concentration — pre-dose a baseline, weeks 4, 12, 24, 36, 52, 76 and 104"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42188","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}